Saturday, June 16, 2018 1:05:43 PM
1. The 510(k) that Arrayit is most likely currently working on is IMO the allergy test, not OvaDx.
2. OvaDx IP and its fate is, as far as we know, still in Avant's hands. And a few years back they changed the strategy to pursue a 510(k) to compete with CA125 test for monitoring instead of PMA for screening. There has been no announcements saying that the IP has reverted back to Arrayit. And Avant has been silent about Ovadx for a long time and is not even mentioning OvaDx on their website anymore.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM